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Background: Scleroderma affects the gastrointestinal (GI) tract in 90% of all cases. Malnutrition, diarrhea, and
constipation are some GI complications that can stem from scleroderma, and they contribute considerably to
impairment in quality of life. Reports of haphazard clusters of high prevalence suggest that environmental exposure
is a risk factor for scleroderma. However, it is largely uncertain whether the GI involvement secondary to
scleroderma is influenced by these environmental factors. This study will review the association between GI
involvement (unintentional weight loss, choking, early satiety, etc.) and environmental exposure in patients with
scleroderma.
Methods/design: Any available observational studies that report GI problems in patients with scleroderma along
with the associated risk factors will be selected. We will search CINAHL, EMBASE, LILACS, MEDLINE, and Web of
Science for relevant articles written in English from June 1884 to May 2014. Identified articles will be screened in
duplicate, and full text for selected articles will be retrieved. Data extraction will be done in duplicate on
sociodemographic characteristics of participants, diagnosis of scleroderma, diagnosis of risk of GI problem, risk
factors reported, etc. Discrepancies will be resolved by consensus or by consulting a third author. We will assess the
participants, methods, and intervention effects of included studies for heterogeneity. Any identified clinical or
statistical heterogeneity will be explored visually or using the chi-square test. Data will be pooled statistically using
the DerSimmonian and Laird random effects method if we have a measure of relative risk and its precision. Our
findings will be reported according to the Meta-Analyses and Systematic Review of Observational Studies (MOOSE)
guideline.
Discussion: Our findings may help patients with scleroderma and health care professionals in preventing GI
morbidity. Knowing that the cost of care for patients with scleroderma increases with more organ involvement,
study findings can inform policy developers to identify ways to curb health care costs.
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Scleroderma, otherwise known as systemic sclerosis, is a
disease manifested by collagen overproduction affecting
various organs including the gastrointestinal (GI) tract [1].
Patients with scleroderma commonly present with inflam-
mation and fibrosis of the skin, vascular abnormalities,
organ damage, and autoantibody production [2]. Diagnosis
is made when these signs and corresponding symptoms are
present [3]. Scleroderma is a debilitating disease that is esti-
mated to affect approximately 16,000 Canadians, impacting
women four to five times more so than men [1]. The preva-
lence of the disease is higher among those of African origin
and varies across countries, appearing higher in North
America and Australia than in Europe and Japan [4].
Scleroderma is associated with debilitating morbidity such
as reduction in mobility and depression [5]. Patients with
this disorder have 30.8% mortality rate, although this num-
ber can vary depending on gender and what visceral organs
are involved [6]. Currently, there are no effective treatments
to combat scleroderma, partly because its pathogenesis
remains unclear [7]. Consequently, much attention has
shifted towards predicting complications secondary to
scleroderma and to manage them appropriately [8]. The
underlying rationale is that it is easier to treat the stage be-
fore these complications arise [8].
The GI tract issues are involved in 90% of all scleroderma
patients and contribute considerably to impairment in qual-
ity of life [9-11]. Malnutrition, nausea, vomiting, diarrhea,
and constipation are some GI complications that can stem
from scleroderma [9]. Reports of nonlinear clusters of high
prevalence suggest that environmental exposure is a risk
factor for scleroderma [11]. For example, silica along with
silicone and epoxy resins have been associated with
increased risk of scleroderma [11]. It is largely uncertain,
however, whether the GI involvement secondary to sclero-
derma is influenced by these environmental factors. This
study will review the association between GI involvement
and environmental exposure in patients with scleroderma.
These findings will help patients with scleroderma and
health care professionals in preventing the GI morbidity. In
Canada, the average annual economic burden of sclero-
derma is estimated to be $18,453 per patient [12]. Knowing
that the cost to care for patients with scleroderma increases
with more organ involvement, the study findings can
inform policy developers to identify ways to curb health
care costs [12].
The overall purpose of this systematic review is to deter-
mine the factors associated with development of GI prob-
lems in patients with scleroderma. We will look for risk
factors for GI problems in patients with scleroderma. These
risk factors include silica, silicone implantation and rupture,
antacid, solvents, epoxy resins, welding fumes, anorexigens,
pentazocine, bromocriptine, L-tryptophan, pesticides, con-
stant hand/arm vibration, and alcohol [13-18]. We willconsider additional risk factors, such as intestinal micro-
biota and food, in the event that we find any studies that
report on them. We will identify and report other predic-
tors of and factors associated with development of GI




Any available observational studies that report on GI
problems in patients with scleroderma along with the
associated risk factors will be selected for the review.
They must have the following criteria:
1. Patients with a formal diagnosis of scleroderma
according to 1980 and 2013 criteria for the diagnosis
of systemic sclerosis by the American College of
Rheumatology [19,20].
2. Clearly reported GI problems.
3. Specific risk factors for GI problems will be studied.
Study settings
Literature from any geographic or socioeconomic setting
will be used.
Types of participants
All participants will be included provided they have sclero-
derma and are assessed for risk factors for GI problems.
Intervention/exposure
We will look for risk factors for GI problems in patients
with scleroderma. These risk factors may include silica,
silicone implantation and rupture, antacid, solvents, epoxy
resins, welding fumes, anorexigens, pentazocine, bromo-
criptine, L-tryptophan, pesticides, constant hand/arm vi-
bration, and alcohol [13-18]. We will consider additional
risk factors, such as intestinal microbiota and food, in the
event that we find any studies that report on them. We
will identify and report other predictors of and factors
associated with development of GI problems in sclero-
derma patients.
Search strategy for identification of studies
We shall attempt to identify all studies relevant to the GI
problems in patients with scleroderma written in English
from June 1884 to May 2014. June 1884 was chosen
because it is the earliest entry of scleroderma in available
databases.
Electronic searches
We will search Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Excerpta Medica database
(EMBASE), Latin American and Caribbean Health Sciences
Literature (LILACS,) Medical Literature Analysis and





3 exp scleroderma, systemic/




8 ((factor$ or feature$ or aspect$ or characteristic$) adj4 (risk)).mp.





14 exp epoxy resins/
15 welding fume$ or welding gas*.mp.






22 hand vibration or arm vibration.mp.
23 exp alcohol drinking/
24 or/6-23
25 exp gastrointestinal tract/
26 exp gastrointestinal diseases/
27 ((problem$ or issue$ or concern$ or complication$) adj3 (alimentary
canal or alimentary tract or digestive tube or digestive tract or GI
tract)).mp.
28 exp weight loss/
29 uninten** weight loss.mp.
30 ((uninten**) adj3 (weight loss)).mp.
31 exp appetite/
32 poor appetite or limited appetite or reduced appetite or sparse
appetite.mp. 34. ((poor or limited or reduced or sparse) adj3
(appetite)).mp.
35 exp deglutition disorders/
36 dysphagia or swallowing disorders.mp.
37 exp gastroesophageal reflux/
38 acid reflux.mp.
39 exp colonic pseudo-obstruction/
40 exp duodenal obstruction/
41 exp intestinal obstruction/
42 exp intestinal pseudo-obstruction/
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for relevant articles written in English from June 1884 to
April 2014. We will use the subject term services of the
different databases. The following search terms and their
medical subject heading (MeSH) equivalents will be used:
scleroderma, risk factors, gastrointestinal, unintentional
weight loss, poor appetite, dysphagia, acid reflux, choking,
early satiety, bloating, nausea, vomiting, constipation, diar-
rhea, antibiotic use, steatorrhea, fecal incontinence, paren-
teral nutrition, and the above listed risk factors. These
terms will be used in varying combinations. Table 1 is a
proposed search strategy for MEDLINE via Ovid.
Reference lists
We will manually check the reference list of all the studies
identified by the above search strategy. Relevant studies
shall be read and included in the review when deemed
appropriate. We will also check the reference list of any
previous reviews on GI problems secondary to scleroderma
for any relevant articles, which could be included in the
review.
Gray literature
We will attempt to contact authors, experts in the field,
research organizations, and conference websites for any
relevant material.
Data collection and analysis
Screening
Two authors (BYH and RJ), working independently, will
screen all citations and abstracts resulting from the search
strategy to identify eligible papers. The full text of eligible
articles will be obtained and assessed using a pre-designed
eligibility form based on the inclusion criteria. Eligible
studies will be included in the review. Disagreements will
be resolved by discussion or by seeking the opinion of a
third party (LT/ML).
Authors will be contacted to clarify missing or unclear
information. Ineligible studies will be excluded from the
review, and the reason for exclusion will be stated in a
table.
Data extraction
The two authors (BYH and RJ) will independently extract
data from the studies using a pre-established data extrac-
tion form. Data will be extracted on sociodemographic
characteristics of participants (age, gender, occupation, resi-
dence), diagnosis of scleroderma, diagnosis of risk of GI
problem, risk factors reported, study design, study setting,
sample size, lost to follow-up/missing data, and strength of
association between risk factors and outcome, if reported.
In order to pool the risk factors for GI problems
among the participants with scleroderma, we will extract
the numbers with each identified risk factor among those
Table 1 Proposed search strategy of ovid (Continued)
43 chok*.mp.
44 early satiety.mp.





50 ((use or prescri** or administ**) adj2 (antibiotic$ or antibacterial$ or
antimicrobial$)).mp.
51 exp steatorrhea/
52 exp fecal incontinence/
53 exp parenteral nutrition/
54 or/25-53
55 5 and 24 and 54
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so we can construct two-by-two tables and use them for
meta-analyses. If only the odds ratios are reported with a
measure of precision (confidence interval or standard
error), we will use this in the meta-analysis.
Assessment of methodological quality
The two authors (BYH and RJ) will independently assess
the methodological quality of included studies using the
Newcastle-Ottawa Scale [21]. We will be assessing publi-
cation bias using funnel plots along with other biases such
as reporting bias, performance bias, and detection bias.
Analyses and reporting
Data synthesis and assessment/investigation of
heterogeneity
We will only pool the results if there is a measure of rela-
tive risk (risk ratio, odds ratio, hazard ratio) and its preci-
sion (95% confidence intervals, standard error, variance).
We will assess the participants, methods, and intervention
effects of included studies for heterogeneity. This will
enable us to determine whether results can be pooled
across studies. Any identified clinical or statistical hetero-
geneity will be explored visually or using the chi-square
test. Possible sources of heterogeneity include the popula-
tion studied, the severity of the condition, the severity of
the exposure, duration of follow-up, etc.
Statistical analysis
Comparison of risk will be made against scleroderma
patients with the risk of GI concerns who have not devel-
oped GI problems. Data will be pooled statistically using
the DerSimmonian and Laird random effects method
where appropriate [22]. The results will be expressed as
odds ratios with 95% confidence interval and p values.Between-study heterogeneity will be tested using Cochran's
Q and the I2 statistic. Stratified analysis of children versus
adults and inpatients versus outpatients may be conducted.
Data will be analyzed using Review Manager version 5.2.
Sensitivity analyses
A sensitivity analysis will be performed to explore how
robust the results are to variations in methodological
quality.
Presenting and reporting of results
The analysis and reporting of the review will be done ac-
cording to the Meta-Analyses and Systematic Review of
Observational Studies (MOOSE) guideline [23]. We will
use a flow diagram to summarize the selection process of
the studies. Agreement between data abstractors will be
assessed using the kappa statistic [24]. A full list of excluded
studies with reasons for exclusion will be reported.
Discussion
GI manifestations secondary to scleroderma are multifa-
ceted depending on the parts of the alimentary tract in-
volved [11]. Severe GI problems are associated with
higher rates of mortality [25]. Studies report that 90% of
scleroderma patients experience GI problems underscor-
ing the quality of life concerns associated with them
[11]. The information obtained from the study will be
important for patients, clinicians, and policy developers.
By identifying and reporting predictors of and factors as-
sociated with GI problems in scleroderma patients along
with early biomarkers that can predict the future severity
of the disease, this study will help clinicians to improve
risk assessment. The resultant earlier and more effective
diagnosis can aid patients in reducing the GI morbidity.
By identifying ways to prevent GI morbidity, this study
can curb the cost of health care in helping scleroderma
patients.
Ethics and dissemination
The results of this paper will be disseminated as peer-
reviewed publications, at conferences and at clinical
rounds.
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